Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25160177 | 0.87 | TLR7 (0.32) | PRMT5WDR77 | |
| SCHEMBL20644471 | 0.83 | SMN1; SMN2 (0.36) | PRMT5WDR77 | |
| SCHEMBL20644439 | 0.81 | PRMT5 (0.37) | PRMT5WDR77CNR1CNR2 | |
| SCHEMBL20644514 | 0.78 | ACACB (0.32) | — | |
| SCHEMBL21538417 | 0.74 | MAPT (0.50) | PRMT5WDR77 | |
| SCHEMBL20644502 | 0.72 | MGLL (0.37) | — | |
| SCHEMBL21169913 | 0.70 | PRMT5 (0.44) | PRMT5WDR77CNR1CNR2 | |
| SCHEMBL25160271 | 0.70 | MAPT (0.48) | — | |
| SCHEMBL25160279 | 0.69 | MAPT (0.37) | — | |
| SCHEMBL20644563 | 0.69 | MAPT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | PRMT5 1075/4885WDR77 4621/4885CNR1 4685/4885 |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | PRMT5 1075/4885WDR77 4621/4885CNR1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.